Reports related to this article:
Project(s): View 4 related projects in PECWeb
Released September 19, 2019 | SUGAR LAND
en
Across the Mid-Atlantic region of the U.S. (Maryland, North Carolina, South Carolina, Virginia and West Virginia), the life science capital construction segment is continuing to experience strong activity and growth.
Industrial Info's Pharma/Bio group is currently reporting on 172 major capital projects valued at $12.2 billion in this region. Click here for a list. The leading life science projects by total investment value in this region include: Novo Nordisk in Clayton, North Carolina ($1.85 billion); Merck in Elkton, Virginia ($1 billion), Merck in Durham, North Carolina ($650 million); and Pfizer in Sanford, North Carolina ($500 million).
See the heat map below, showing the amount of Pharma/Bio activity in the region.
Industrial Info's Pharma/Bio group is currently reporting on 172 major capital projects valued at $12.2 billion in this region. Click here for a list. The leading life science projects by total investment value in this region include: Novo Nordisk in Clayton, North Carolina ($1.85 billion); Merck in Elkton, Virginia ($1 billion), Merck in Durham, North Carolina ($650 million); and Pfizer in Sanford, North Carolina ($500 million).
See the heat map below, showing the amount of Pharma/Bio activity in the region.
